Worthing, United Kingdom
Worthing, United Kingdom
SEARCH FILTERS
Time filter
Source Type

— GlobalData's clinical trial report, “Allergies Global Clinical Trials Review, H1, 2017" provides an overview of Allergies clinical trials scenario. This report provides top line data relating to the clinical trials on Allergies. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Key players covered in the report are ALK-Abello A/S, Circassia Pharmaceuticals Plc, Stallergenes Greer plc, Merck & Co Inc, Allergy Therapeutics Plc, Novartis AG, Merck KGaA, Droege International Group AG, Japan Tobacco Inc, and Aimmune Therapeutics Inc. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Reasons to buy - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level GlobalData's clinical trial report, “Allergic Asthma Global Clinical Trials Review, H1, 2017" provides an overview of Allergic Asthma clinical trials scenario. This report provides top line data relating to the clinical trials on Allergic Asthma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process. Key players covered in the report are Novartis AG, F. Hoffmann-La Roche Ltd, AstraZeneca Plc, GlaxoSmithKline Plc, Merck KGaA, Merck & Co Inc, Laboratorios LETI SL, ALK-Abello A/S, Quintiles IMS Holdings Inc, and Kuros Biosciences AG The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Reasons to buy - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level About Us: Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customised reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialisation. This helps our clients to map their needs and we produce the perfect required market research study for our clients. For more information, please visit http://www.orbisresearch.com/reports/index/allergies-global-clinical-trials-review-h1-2017


News Article | July 18, 2017
Site: globenewswire.com

18 July 2017 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, today provides a trading update for the year ended 30 June 2017 ahead of its Preliminary Results to be announced in September 2017. Revenues for the year are expected to be ahead of market expectations at £64.1m (2016: £48.5m). This strong performance represents 15% annual growth on a constant currency basis and 32% on a reported basis which reflects the favourable euro exchange rate. The Company is continuing to gain market share within its core markets in Europe. Revenues have grown over the past 18 years at a double-digit compound annual growth rate. Research and development expenditure for the 2017 financial year is anticipated to be lower than market expectations due to the phasing of activities across the year end and these costs will now be incurred in financial year 2018. The ongoing pipeline trials continue to progress well and timing remains in line with Board expectations. The cash balance at the end of June 2017 was £22.1m (30 June 2016: £23.4m). Allergy Therapeutics' market penetration has continued with strong growth in Pollinex Quattro and Pollinex. Venomil sales have also performed well due to the pre-stocking of raw materials compared to elsewhere in the market where there have been shortages of stock. Sales of the newer products in the Group's portfolio (Synbiotics and Acarovac) continue to develop well. In Europe, recruitment of patients for the pivotal Phase III PQ Birch trial is on track with the trial still expected to start in the autumn of 2017. Likewise for the US, the Phase II Grass MATA MPL trial is also still planned to start this autumn. Patients for the Acarovac Quattro Phase I trial are being recruited and results continue to be expected in the autumn of 2018. Manuel Llobet, Chief Executive Officer of Allergy Therapeutics, commented: "Revenue growth of 15% at constant currency reflects the continued strong performance of the product portfolio and its growing market share. Our successful strategy focuses on our patient-convenient products and controlled investment in our development pipeline to expand our addressable market. Our double digit CAGR of revenue over the past 18 years demonstrates that we have a robust, reliable and successful business model." This announcement contains insider information for the purposes of Article 7 of Regulatory (EU) No596/2014. For further information, please contact: About Allergy Therapeutics Allergy Therapeutics is an international specialty pharmaceutical group focussed on the treatment and diagnosis of allergic disorders including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary products and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development. Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories.  The Group employs c.500 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.


— Market Pipeline Report Peanut Allergy Pipeline Review, H1 2017, provides an overview of the Peanut Allergy (Oncology) pipeline landscape. The report covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Browse the 23 Tables and 11 Figures, 12 Company Profiles, Spread across 84 Pages Report Available at http://www.reportsnreports.com/reports/992907-peanut-allergy-pipeline-review-h1-2017.html . Peanut Allergy market companies are Adverum Biotechnologies Inc, Aimmune Therapeutics Inc, Alfacyte Ltd, Allergy Therapeutics Plc,AnaptysBio Inc, ASIT Biotech SA, Astellas Pharma Inc, BioLingus AG,DBV Technologies SA,HAL Allergy BV, Intrommune Therapeutics, Sanofi. Peanut allergy is common, especially in children. An allergic response to peanuts usually occurs within minutes after exposure, and symptoms range from mild to severe. Peanut allergy signs and symptoms can include skin reactions, such as hives, redness or swelling, itching or tingling in or around the mouth and throat, digestive problems, such as diarrhea, stomach cramps, nausea or vomiting, tightening of the throat, shortness of breath or wheezing and runny nose. Place Order to This Report at http://www.reportsnreports.com/purchase.aspx?name=992907 The Peanut Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Peanut Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 4, 8 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Discovery stages comprises 1, 1 and 1 molecules, respectively. Scope • The pipeline guide provides a snapshot of the global therapeutic landscape of Peanut Allergy (Immunology). • The pipeline guide reviews pipeline therapeutics for Peanut Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources. • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. • The pipeline guide reviews key companies involved in Peanut Allergy (Immunology) therapeutics and enlists all their major and minor projects. • The pipeline guide evaluates Peanut Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. • The pipeline guide reviews latest news related to pipeline therapeutics for Peanut Allergy (Immunology) Reasons to buy • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. • Find and recognize significant and varied types of therapeutics under development for Peanut Allergy (Immunology). • Classify potential new clients or partners in the target demographic. • Develop tactical initiatives by understanding the focus areas of leading companies. • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. • Formulate corrective measures for pipeline projects by understanding Peanut Allergy (Immunology) pipeline depth and focus of Indication therapeutics. • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. About Us: ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. For more information, please visit http://www.reportsnreports.com/reports/992907-peanut-allergy-pipeline-review-h1-2017.html


Kramer M.F.,Bencard Allergie GmbH | Heath M.D.,Allergy Therapeutics
Vaccine | Year: 2014

We are living in an "aluminium age" with increasing bioavailability of the metal for approximately 125 years, contributing significantly to the aluminium body burden of humans. Over the course of life, aluminium accumulates and is stored predominantly in the lungs, bones, liver, kidneys and brain. The toxicity of aluminium in humans is briefly summarised, highlighting links and possible causal relationships between a high aluminium body burden and a number of neurological disorders and disease states.Aluminium salts have been used as depot-adjuvants successfully in essential prophylactic vaccinations for almost 100 years, with a convincing positive benefit-risk assessment which remains unchanged.However, allergen-specific immunotherapy commonly consists of administering a long-course programme of subcutaneous injections using preparations of relevant allergens. Regulatory authorities currently set aluminium limits for vaccines per dose, rather than per treatment course. Unlike prophylactic vaccinations, numerous injections with higher proportions of aluminium-adjuvant per injection are applied in subcutaneous immunotherapy (SCIT) and will significantly contribute to a higher cumulative life dose of aluminium. While the human body may cope robustly with a daily aluminium overload from the environment, regulatory cumulative threshold values in immunotherapy need further addressing. Based on the current literature, predisposing an individual to an unusually high level of aluminium, such as through subcutaneous immunotherapy, has the potential to form focal accumulations in the body with the propensity to exert forms of toxicity. Particularly in relation to longer-term health effects, the safety of aluminium adjuvants in immunotherapy remains unchallenged by health authorities - evoking the need for more consideration, guidance, andtransparency on what is known and not known about its safety in long-course therapy and what measures can be taken to prevent or minimise its risks. The possibility of providing an effective means of measuring aluminium accumulation in patients undergoing long-term SCIT treatment as well as reducing their aluminium body burden is discussed. © 2014 The Authors.


CTA approval in Spain for Phase I AM101 clinical study evaluating safety of adjuvanted, modified house dust mite allergy vaccine CTA approval in Spain for Phase I AM101 clinical study evaluating safety of adjuvanted, modified house dust mite allergy vaccine Allergy Therapeutics ( : AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today announces that the Phase I clinical study investigating the safety and tolerability of Acarovac MPL (monophosphoryl lipid A) has received Clinical Trial Application (CTA) approval in Spain. House dust mites are a major cause of perennial allergic rhinitis and allergic asthma1. Acarovac MPL builds on the strong foundation of technologies employed in the successful Pollinex® Quattro range of subcutaneous allergy immunotherapies, and builds on the demonstrated efficacy2 of the existing successful product platform of Acarovac Plus™, the fastest growing "named-patient product" in Allergy Therapeutics' Spanish subsidiary. Acarovac MPL is the only house-dust mite immunotherapy in development utilising MCT® (microcrystalline tyrosine), a natural, biodegradable depot, and the adjuvant MPL for the treatment of perennial allergic rhinitis making this vaccine unique in a $1.5 billion per annum market3. CTA approval has been granted and the Company now expects this formulation to begin Phase I studies immediately, to assess the safety and tolerability of two different dose regimens. Both treatment regimens include a two-to-four week initial up-dosing phase but differ in the duration of the later maintenance phase. The Phase I trial of 32 patients is expected to last one year, and to be delivered on-time in-line with the Company's stated strategic plan when funding the programme in November 2015. If the Phase I trial is successful, the Company expects to launch Acarovac MPL in Spain on a named-patient basis. Commenting on the CTA approval, Manuel Llobet, Chief Executive Officer of Allergy Therapeutics, said: "By using the successful biodegradable adjuvant system of MCT® and MPL, integral in our seasonal marketed vaccines, in a perennial house dust mite vaccine, we aim to improve both safety and efficacy for the thousands of patients who suffer year-round due to house dust mite allergy. Acarovac Quattro will provide convenience to our patients and doctors and more efficient pharmacoeconomics. Effectively, the dosing regime in Acarovac Quattro has the potential to improve the convenience, adherence and compliance that is essential for a successful treatment, and builds on the acceptance of the existing Acarovac Plus platform." About Allergy Therapeutics Allergy Therapeutics is an international specialty pharmaceutical company focussed on the treatment and diagnosis of allergic disorders including immunotherapy vaccines that cure disease. The Company sells proprietary products and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with MHRA-approved manufacturing facilities. The Company employs c.495 employees and is listed on the London Stock Exchange ( : AGY). For more information, please see www.allergytherapeutics.com. References 1. Calderón M et al., Respiratory allergy caused by house dust mites: What do we really know? J Allergy Clin Immunol. 2015 Jul;136(1):38-48 2. Roger, A., Depreux, N., Jurgens Y., Heath M, Garcia G., Skinner M, A novel and well tolerated mite allergoid subcutaneous immunotherapy: Evidence of clinical and immunologic efficacy. Immunity, Inflammation and Disease, 2014; 2 (2); 92-98 3. QYR Pharma report. September 2016 This information is provided by RNS The company news service from the London Stock Exchange


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Allergy Immunotherapy Market: Size, Trends & Forecasts (2016-2020)" report to their offering. Global Allergy Immunotherapy Market: Size, Trends & Forecasts (2016-2020), provides an in-depth analysis of the global allergy immunotherapy market by value, by methods of administration, by region, etc. The report provides a regional analysis of the allergy immunotherapy market, including the following regions: the US, Europe and Rest of the World. The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global allergy immunotherapy market has also been forecasted for the period 2016-2020, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. Allergy refers to a condition in which the immune system abnormally reacts to the foreign substance. The foreign substance could be in the form of particular food, pollen, pets, metals, fur, dust, etc. to which the body becomes hypersensitive when comes into contact. The foreign substance that triggers the hypersensitive response in the body is known as an allergen. Generally, most substances that cause allergies are normally harmless to the human body and have no effect on the vast majority of people that are not allergic. Allergy is not a disease, it is a mere over-reaction of body to the foreign substance that is not harmful. To diagnose an allergy skin test, blood test and allergy component tests are undertaken. Allergies are generally seasonal and perennial in nature. The global allergy immunotherapy market has increased at a significant CAGR during the years 2009-2015 and projections are made that the market would rise in the next four years i.e. 2016-2020 tremendously. The allergy immunotherapy market is expected to increase due to growth in healthcare expenditure, rising incidence of chronic diseases and increasing global pollution, etc. Yet the market faces some challenges such as, lack of treatment awareness, lack of investor confidence, anaphylaxia, huge treatment costs, etc. The key players of the allergy immunotherapy market ALK-Abello, Allergy Therapeutics, Merck Group and Stallergenes, who are also profiled with their financial information and respective business strategies. For more information about this report visit http://www.researchandmarkets.com/research/khp5ht/global_allergy


News Article | November 30, 2016
Site: www.newsmaker.com.au

The report titled “Global Allergy Immunotherapy Market: Size, Trends & Forecasts (2016-2020)”, provides an in-depth analysis of the global allergy immunotherapy market by value, by methods of administration, by region, etc. The report provides a regional analysis of the allergy immunotherapy market, including the following regions: the US, Europe and Rest of the World. Complete report available at http://www.marketreportsonline.com/540890.html. The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global allergy immunotherapy market has also been forecasted for the period 2016-2020, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. The key players of the allergy immunotherapy market ALK-Abello, Allergy Therapeutics, Merck Group and Stallergenes, who are also profiled with their financial information and respective business strategies. Allergy refers to a condition in which the immune system abnormally reacts to the foreign substance. The foreign substance could be in the form of particular food, pollen, pets, metals, fur, dust, etc. to which the body becomes hypersensitive when comes into contact. The foreign substance that triggers the hypersensitive response in the body is known as an allergen. Generally, most substances that cause allergies are normally harmless to the human body and have no effect on the vast majority of people that are not allergic. Allergy is not a disease, it is a mere over-reaction of body to the foreign substance that is not harmful. To diagnose an allergy skin test, blood test and allergy component tests are undertaken. Allergies are generally seasonal and perennial in nature. Purchase a copy of this “Allergy Immunotherapy Market” research reports at http://www.marketreportsonline.com/contacts/purchase.php?name=540890. The global allergy immunotherapy market has increased at a significant CAGR during the years 2009-2015 and projections are made that the market would rise in the next four years i.e. 2016-2020 tremendously. The allergy immunotherapy market is expected to increase due to growth in healthcare expenditure, rising incidence of chronic diseases and increasing global pollution, etc. Yet the market faces some challenges such as, lack of treatment awareness, lack of investor confidence, anaphylaxia, huge treatment costs, etc. Other Related Reports from Pharmaceuticals Market Research Reports at http://www.marketreportsonline.com/cat/pharmaceuticals-market-research.html. About Us: MarketReportsOnline comprises of an online library of 2,50,000 reports and in-depth market research studies of over 5000+ micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.


— Complete report on Allergy Immunotherapy market spread across 85 pages providing 4 company profiles and 6 tables and 38 figures is now available at http://www.marketreportsonline.com/540890.html. The report titled “Global Allergy Immunotherapy Market: Size, Trends & Forecasts (2016-2020)”, provides an in-depth analysis of the global allergy immunotherapy market by value, by methods of administration, by region, etc. The report provides a regional analysis of the allergy immunotherapy market, including the following regions: the US, Europe and Rest of the World. Complete report available at http://www.marketreportsonline.com/540890.html. The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global allergy immunotherapy market has also been forecasted for the period 2016-2020, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. The key players of the allergy immunotherapy market ALK-Abello, Allergy Therapeutics, Merck Group and Stallergenes, who are also profiled with their financial information and respective business strategies. Country Coverage • Europe • Rest of the World • US Allergy refers to a condition in which the immune system abnormally reacts to the foreign substance. The foreign substance could be in the form of particular food, pollen, pets, metals, fur, dust, etc. to which the body becomes hypersensitive when comes into contact. The foreign substance that triggers the hypersensitive response in the body is known as an allergen. Generally, most substances that cause allergies are normally harmless to the human body and have no effect on the vast majority of people that are not allergic. Allergy is not a disease, it is a mere over-reaction of body to the foreign substance that is not harmful. To diagnose an allergy skin test, blood test and allergy component tests are undertaken. Allergies are generally seasonal and perennial in nature. Purchase a copy of this “Allergy Immunotherapy Market” research reports at http://www.marketreportsonline.com/contacts/purchase.php?name=540890. The global allergy immunotherapy market has increased at a significant CAGR during the years 2009-2015 and projections are made that the market would rise in the next four years i.e. 2016-2020 tremendously. The allergy immunotherapy market is expected to increase due to growth in healthcare expenditure, rising incidence of chronic diseases and increasing global pollution, etc. Yet the market faces some challenges such as, lack of treatment awareness, lack of investor confidence, anaphylaxia, huge treatment costs, etc. Few Points from List of Figures: Figure 1: Mechanism of Allergy Figure 2: Diagnosis of Allergy Figure 3: Nature of Allergy Figure 4: Types of Allergy Figure 5: Types of Allergens Figure 6: Types of Immunotherapy Figure 7: Immunotherapy by Methods of Administration Figure 8: Global Allergy Immunotherapy Market by Value; 2009-2015 (US$ Billion) Figure 9: Global Allergy Immunotherapy Market by Value; 2016-2020 (US$ Billion) Figure 10: Global Allergy Immunotherapy Market by Geography; 2015 (Percentage, %) Figure 11: Global Allergy Immunotherapy Market by Method of Administration; 2015 (Percentage, %) Figure 12: Global Subcutaneous Immunotherapy Market by Value; 2009-2015 (US$ Million) Figure 13: Global Subcutaneous Immunotherapy Market by Value; 2016-2020 (US$ Million) Figure 14: Global Sublingual Immunotherapy Solution Market by Value; 2009-2015 (US$ Million) Figure 15: Global Sublingual Immunotherapy Solution Market by Value; 2016-2020 (US$ Million) Other Related Reports from Pharmaceuticals Market Research Reports at http://www.marketreportsonline.com/cat/pharmaceuticals-market-research.html. For more information, please visit http://www.marketreportsonline.com/540890.html


Patent
Allergy Therapeutics and Corixa Corporation | Date: 2011-05-18

A method of producing a mucosal and systemic immune response in a mammal comprising administering sublingually effective amount of a composition comprising at least one antigen and a glycolipid adjuvant to said mammal.


Patent
Allergy Therapeutics | Date: 2012-04-20

A method of preparing a composition comprising one or more antigens adsorbed to an amino acid wherein said method comprises: (i) mixing a solution of one or more antigens with a solution of the amino acid in an aqueous acid whilst neutralising the mixture of solutions, thereby forming an adsorbate comprising the one or more antigens and the amino acid; (ii) separating the adsorbate into a desired buffer by cross-flow filtration thereby forming said composition; and (iii) recovering said composition; wherein steps (i) to (iii) are performed in a sterile environment and within a closed system.

Loading Allergy Therapeutics collaborators
Loading Allergy Therapeutics collaborators